Other languages Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
9.73 ^USD	-2.01%		+3.07%	-3.28%

May. 02	Transcript : Vir Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02	Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Cytokinetics Appoints Sung Lee as CFO	Apr. 26
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024	Apr. 18
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule	Mar. 05
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	Mar. 05
Vir Biotechnology's Q4 Loss Widens, Revenue Declines	Feb. 23
Vir Biotechnology, Inc. and Glaxo Wellcome UK Limited Mutually Agrees to Terminate Collaboration on the Influenza Program Under the DCA	Feb. 22
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22
Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer	Feb. 20
Vir Biotechnology to Eliminate Roles, Close Facilities to Cut Costs	Dec. 13
Vir Biotechnology to cut about 75 jobs, shut some facilities	Dec. 13
Vir Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Vir Biotechnology, Inc. Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer	23-10-30
Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD?s the Liver Meeting® 2023	23-10-11
Vir Biotechnology Gets $50 Million in US Government Funding to Support Antibody Platform Technologies Development	23-10-03
Vir Biotechnology, Inc. Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV	23-09-20
Vir Biotechnology Operations Chief Friedl-Naderer Departing	23-09-20
Vir Biotechnology, Inc. Announces That Johanna Friedl-Naderer, the Company?s Executive Vice President and Chief Operating Officer, Will Be Leaving the Company on September 29, 2023	23-09-20
Vir Biotechnology's Near-Term Trial Readout in Hepatitis B Unlikely to Boost Sentiment, BofA Securities Says	23-09-08
Vir Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Other languages

Filters